Omeros Stock Falls 12% After EMA Committee Reaffirms Negative Narsoplimab Opinion
Omeros Corp. (OMER) shares fell 12% to $16.53 after the European Medicines Agency's committee reaffirmed its negative opinion on narsoplimab for a specific treatment. The stock traded between $15.89 and $17.94. Omeros plans to provide access in Europe and continues U.S. commercialization of YARTEMLEA, approved by the FDA in 2025.
How this was made
The 30-second read
Why it matters
A reaffirmed negative EMA stance reduces the likelihood of near-term EU approval, which can pressure valuation multiples for biotech programs even when the product is already FDA-approved in the U.S.
Market read
This is a direct regulatory catalyst tied to a same-day, double-digit stock move, making it actionable for traders focused on biotech approval risk.
What to watch
The article does not quantify any probability of appeal, resubmission, or alternative EU pathways; traders may be over-discounting without knowing next regulatory steps.
Background
The EMA committee re-examined its June 2026 negative opinion on Omeros’ narsoplimab marketing authorization application for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
Ticker impact
Omeros shares fell 12% after the EMA committee reaffirmed a negative opinion on its narsoplimab marketing authorization application for TA-TMA.
Likely continued downside or elevated volatility as traders price in delayed or reduced European approval prospects.
The article ties the same-day double-digit drop directly to the EMA committee reaffirming a negative opinion after re-examination, a clear near-term catalyst.
Market effects
Highlights regulatory risk for rare-disease biotech seeking EU marketing authorization, potentially weighing on sentiment for similar TA-TMA/hematology assets.
EU reimbursement and access expectations for the therapy are likely to remain constrained, affecting European biotech sentiment.
Reinforces that even after FDA approval, EU review outcomes can diverge, shaping global risk perception for cross-region commercialization.
Counterpoint
U.S. commercialization of YARTEMLEA continues, so the EMA negative opinion may be partially offset by ongoing U.S. revenue momentum and named-patient access efforts.
Key entities
- companyOmeros Corp.
NASDAQ-listed biotech whose narsoplimab (YARTEMLEA in the U.S.) faces a reaffirmed negative EMA opinion for TA-TMA.
- regulatorEuropean Medicines Agency (EMA) Committee for Medicinal Products for Human Use
EU committee that reaffirmed a negative opinion after re-examination of Omeros’ marketing authorization application.
- drugnarsoplimab
Therapy at the center of the EMA marketing authorization decision for TA-TMA.
